Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter F Mount

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Kidney International|May 24, 2025
A randomized controlled trial of intravenous immunoglobulin vs standard of care for the treatment of chronic active antibody-mediated rejection in kidney transplant recipientsWilliam R Mulley, Dhakshayini Tharmaraj, Kevan R Polkinghorne, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 15, 2024
The AMPK activator ATX-304 alters cellular metabolism to protect against cisplatin-induced acute kidney injuryMarina Katerelos, Kurt Gleich, Geoff Harley, et al.
American Journal of Physiology. Renal Physiology|June 21, 2013
AMPK couples plasma renin to cellular metabolism by phosphorylation of ACC1Scott A Fraser, Suet-Wan Choy, Núria M Pastor-Soler, et al.
Blood Purification|January 23, 2020
A tRial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in HemoDialysis Patients: A Safety Device StudyRathika Krishnasamy, Carmel M Hawley, Meg J Jardine, et al.
Trials|May 27, 2020
Study Protocol for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a pragmatic, registry-based, multi-center, double-blind, randomized controlled trial evaluating the effect of intravenous fluid therapy with Plasma-Lyte 148 versus 0.9% saline on delayed graft function in deceased donor kidney transplantationMichael G Collins, Magid A Fahim, Elaine M Pascoe, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|March 29, 2021
Effect of a medium cut-off dialyzer on protein-bound uremic toxins and mineral metabolism markers in patients on hemodialysisMark K Tiong, Rathika Krishnasamy, Edward R Smith, et al.
Lancet (London, England)|June 21, 2023
Balanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised, controlled trialMichael G Collins, Magid A Fahim, Elaine M Pascoe, et al.
Transplantation Direct|December 8, 2022
Baseline Characteristics and Representativeness of Participants in the BEST-Fluids Trial: A Randomized Trial of Balanced Crystalloid Solution Versus Saline in Deceased Donor Kidney TransplantationMichael G Collins, Magid A Fahim, Elaine M Pascoe, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Kidney International|May 24, 2025
A randomized controlled trial of intravenous immunoglobulin vs standard of care for the treatment of chronic active antibody-mediated rejection in kidney transplant recipientsWilliam R Mulley, Dhakshayini Tharmaraj, Kevan R Polkinghorne, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 15, 2024
The AMPK activator ATX-304 alters cellular metabolism to protect against cisplatin-induced acute kidney injuryMarina Katerelos, Kurt Gleich, Geoff Harley, et al.
American Journal of Physiology. Renal Physiology|June 21, 2013
AMPK couples plasma renin to cellular metabolism by phosphorylation of ACC1Scott A Fraser, Suet-Wan Choy, Núria M Pastor-Soler, et al.
Blood Purification|January 23, 2020
A tRial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in HemoDialysis Patients: A Safety Device StudyRathika Krishnasamy, Carmel M Hawley, Meg J Jardine, et al.
Trials|May 27, 2020
Study Protocol for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a pragmatic, registry-based, multi-center, double-blind, randomized controlled trial evaluating the effect of intravenous fluid therapy with Plasma-Lyte 148 versus 0.9% saline on delayed graft function in deceased donor kidney transplantationMichael G Collins, Magid A Fahim, Elaine M Pascoe, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|March 29, 2021
Effect of a medium cut-off dialyzer on protein-bound uremic toxins and mineral metabolism markers in patients on hemodialysisMark K Tiong, Rathika Krishnasamy, Edward R Smith, et al.
Lancet (London, England)|June 21, 2023
Balanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised, controlled trialMichael G Collins, Magid A Fahim, Elaine M Pascoe, et al.
Transplantation Direct|December 8, 2022
Baseline Characteristics and Representativeness of Participants in the BEST-Fluids Trial: A Randomized Trial of Balanced Crystalloid Solution Versus Saline in Deceased Donor Kidney TransplantationMichael G Collins, Magid A Fahim, Elaine M Pascoe, et al.
Pageof 5